Alnylam gets $700m Sanofi investment, buys Sirna from Merck
This article was originally published in Scrip
Executive Summary
Sanofi's Genzyme business has invested $700m in a 12% stake in Alnylam Pharmaceuticals as part of an expansion of the alliance the two firms formed around Alnylam's lead product, patisiran, in 2012. Separately, Alnylam announced that it will acquire Sirna Therapeutics, a rival RNAi business, from Merck & Co, for $175m plus milestones.
You may also be interested in...
Up Front Or Back End? Considering The Best Structure For Milestone Fees
PwC partner Dmitri Drone explained that a deal for an asset with high commercial expectations is best structured with more emphasis on pre-approval than post-approval payments. A post-approval focus on shared risk is more appropriate when an asset is licensed at an earlier stage of development.
Alnylam Plays Up Patisiran As Polyneuropathy Drug Nears Filings
Open-label extension Phase II data with RNAi candidate shows patients with transthyretin-mediated amyloidosis polyneuropathy may be regaining sensation and possibly even regenerating nerves.
How Humira Finally Lost The Top Spot In Drug Sales
AbbVie’s Humira has been the world’s best-selling drug since 2012, and if it hadn’t been for COVID-19 it would most likely have been on track to retain its position for the 10th year in row.